¼¼°èÀÇ ¿©¼º °Ç°­ Ä¡·á ½ÃÀå
Women¢¥s Health Therapeutics
»óǰÄÚµå : 1514248
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 92 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,260,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,780,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀº 2030³â±îÁö 454¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

2023³â¿¡ 196¾ï ´Þ·¯·Î Æò°¡µÈ ¿©¼º ¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀº ºÐ¼® ±â°£¿¡ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 12.7%·Î ¼ºÀåÇϰí 2030³â¿¡´Â 454¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Æó°æ ÈÄ °ñ´Ù°øÁõ ¾ÖÇø®ÄÉÀ̼ÇÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 14.9%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 181¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. È£¸£¸ó ºÒÀÓ ÀÀ¿ë ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 10.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 51¾ï ´Þ·¯·Î Æò°¡µÈ ¹Ý¸é Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 17.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ ¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀº 2023³â 51¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 113¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 17.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) °¢°¢ 8.4%¿Í 10.7%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) ¾à 9.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¿©¼º °Ç°­ Ä¡·á ½ÃÀå - ÁÖ¿ä ÃËÁø¿äÀΰú µ¿Çâ ¿ä¾à

¿©¼º °Ç°­ Ä¡·á´Â ¿©¼º¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â °Ç°­ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ Æ¯º°È÷ ¼³°èµÈ ±¤¹üÀ§ÇÑ Ä¡·á ¹× ¼Ö·ç¼ÇÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ Ä«Å×°í¸®¿¡´Â À¯¹æ¾Ï, ÀڱðæºÎ¾Ï, °ñ´Ù°øÁõ, °»³â±â Àå¾Ö, »ý½Ä±â´É Àå¾Ö µî ¿©¼º ƯÀ¯ ¶Ç´Â ¿©¼º¿¡¼­ ÈçÈ÷ ¹ß°ßµÇ´Â ÁúȯÀ» ´ë»óÀ¸·Î ÇÑ ¾à¹° Ä¡·á, Ä¡·á¹ý, ¿¹¹æ Ä¡·á°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Ä¡·áÁ¦´Â ´Ù¾çÇÑ ¶óÀÌÇÁ ½ºÅ×ÀÌÁö¿¡ ÀÖ´Â ¿©¼ºÀÇ QOL(»ýȰÀÇ Áú)°ú °Ç°­ »óŸ¦ °³¼±Çϰí, ½Åü¿Í »ý½Ä ¾ç¸éÀÇ °Ç°­À» Áö¿øÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù. »çÃá±âºÎÅÍ Æó°æ ÈıîÁö ´Ù¾çÇÑ ¶óÀÌÇÁ ½ºÅ×ÀÌÁö ¿©¼º¿¡ ´ëÀÀÇÏ´Â °Ç°­ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö´Â °¡¿îµ¥ ¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀ» °ßÀÎÇÏ´Â °ÍÀº ¸î °¡Áö Áß¿äÇÑ ¿äÀÎÀ̸ç, ƯÈ÷ ¿©¼ºÀÇ °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνİúÁöÁö Áõ°¡ÀÔ´Ï´Ù. °øÁß À§»ý Ä·ÆäÀΰú ¿©¼º ¿ËÈ£ ´Üü´Â À¯¹æ¾Ï°ú ³­¼Ò¾Ï µîÀÇ Áúº´¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í Á¶±â Áø´Ü°ú Á¶±â Ä¡·á¿¡ ¿¬°áÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ³ëÀÎ ¿©¼ºÀº ½ÉÇ÷°ü Áúȯ, °ñ´Ù°øÁõ, Æó°æ µîÀÇ ¸¸¼º °Ç°­ ¹®Á¦¸¦ °æÇèÇÒ °¡´É¼ºÀÌ ³ô±â ¶§¹®ÀÔ´Ï´Ù. °Ô´Ù°¡ ÀǾàǰ°ú »ý¸í°øÇÐÀÇ ¹ßÀüÀ¸·Î ¿©¼º ƯÀ¯ÀÇ Áúº´¿¡ ´ëÇÑ º¸´Ù È¿°úÀûÀÎ Ä¡·á¹ýÀÌ °³¹ßµÇ¾î ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ¼ö¸íÀ» ¿¬ÀåÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸¿¡´Â È£¸£¸ó º¸Ãæ ¿ä¹ý, Ç¥Àû ¾Ï Ä¡·á, ºÒÀÓ Ä¡·á °³¼± µîÀÌ Æ÷ÇÔµÇ¾î ¸ðµÎ ÃÖ±Ù Å« Çõ½Å°ú ä¿ëÀ» º¼ ¼ö ÀÖ½À´Ï´Ù.

¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀÇ ÃÖ±Ù µ¿ÇâÀº ¸ÂÃãÇü ÀÇ·á ¹× Ç¥Àû Ä¡·á·ÎÀÇ ÀüȯÀ» º¸¿©ÁÝ´Ï´Ù. ƯÈ÷ À¯¹æ¾ÏÀ̳ª ³­¼Ò¾Ï µî ¹ÙÀÌ¿À¸¶Ä¿³ª À¯ÀüÀڰ˻翡 ÀÇÇØ Ä¡·áÈ¿°ú¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ´Â ºÐ¾ß¿¡¼­´Â °³º° ȯÀÚÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ̳ª ºÐÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá Ä¡·á¹ýÀÇ °³¹ß¿¡ ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æó°æ±â Áõ»óÀ» °ü¸®Çϱâ À§ÇÑ ºñÈ£¸£¸ó ¿ä¹ýÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̰ÍÀº ½É°¢ÇÑ ºÎÀÛ¿ëÀ» µ¿¹ÝÇÒ ¼ö ÀÖ´Â ÀüÅëÀûÀΠȣ¸£¸ó º¸Ãæ ¿ä¹ýÀ» ´ëüÇÏ´Â Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ µÞ¹ÞħÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¸ñÇÒ¸¸ÇÑ µ¿ÇâÀº ¸ð¹ÙÀÏ °Ç°­ ¾Û°ú ¿þ¾î·¯ºí µð¹ÙÀ̽º¸¦ Æ÷ÇÔÇÑ µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕÀ¸·Î Áß¿äÇÑ °Ç°­ ÁöÇ¥¸¦ ÃßÀûÇÏ°í °³ÀÎÈ­µÈ °Ç°­ ÀλçÀÌÆ®À» Á¦°øÇÏ¿© ¿©¼º °Ç°­ °ü¸®¸¦ Áö¿øÇÕ´Ï´Ù. Çϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¿©¼ºÀÌ ÀÚ½ÅÀÇ °Ç°­À» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ¸ç ´Ù¾çÇÑ °Ç°­ »óÅÂÀÇ ¿¹¹æ, Á¶±â ¹ß°ß ¹× °ü¸®¸¦ À§ÇÑ µµ±¸¸¦ Á¦°øÇÕ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 36»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Women's Health Therapeutics Market to Reach US$45.4 Billion by 2030

The global market for Women Women's Health Therapeutics estimated at US$19.6 Billion in the year 2023, is expected to reach US$45.4 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2023-2030. Postmenopausal Osteoporosis Application, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$18.1 Billion by the end of the analysis period. Growth in the Hormonal Infertility Application segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 17.0% CAGR

The Women's Health Therapeutics market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 17.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 10.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.

Global Women's Health Therapeutics Market - Key Drivers and Trends Summarized

Women's health therapeutics encompass a broad range of medical treatments and solutions specifically designed to address health issues that affect women. This category includes medications, therapies, and preventive treatments targeting conditions unique to or more prevalent in women, such as breast cancer, cervical cancer, osteoporosis, menopause, and reproductive health disorders. These therapeutics aim to improve the quality of life and health outcomes for women across various life stages, supporting both physical and reproductive health. With an increasing demand for health services that cater to women through various stages of life—from puberty to post-menopause—the landscape of women's health therapeutics is expanding.

The market for women's health therapeutics is driven by several key factors, notably the increasing awareness and advocacy around women's health issues. Public health campaigns and women's advocacy groups have been pivotal in increasing awareness about diseases such as breast and ovarian cancer, leading to earlier diagnosis and treatment. The aging female population globally is another significant driver, as older women are more likely to experience chronic health issues such as cardiovascular diseases, osteoporosis, and menopausal health concerns. Furthermore, advancements in pharmaceuticals and biotechnology have led to the development of more effective treatments for conditions specific to women, enhancing patient outcomes and extending life expectancies. These advancements include hormone replacement therapies, targeted cancer therapies, and improved fertility treatments, which have all seen significant innovation and adoption in recent years.

Recent trends in the women's health therapeutics market indicate a shift towards personalized medicine and targeted therapies. There is a growing focus on developing treatments tailored to the genetic and molecular profiles of individual patients, particularly in areas such as breast and ovarian cancer, where biomarkers and genetic tests can predict treatment responses. Additionally, there is an increasing investment in research and development of non-hormonal therapies for managing menopause symptoms, driven by the demand for alternatives to traditional hormone replacement therapies, which can have significant side effects. Another notable trend is the integration of digital health technologies, including mobile health apps and wearable devices, designed to support women's health management by tracking vital health metrics and providing personalized health insights. These technologies are playing a crucial role in empowering women to take charge of their health, offering tools for prevention, early detection, and management of various health conditions

Select Competitors (Total 36 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â